<div id="readability-page-1"><div> By Katherine Hamilton <pre></pre> MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories. The stock advanced 7% to $13.14 in pre-market trading Wednesday. The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected. Revenue growth was driven by a 22% increase in international sales. MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems. The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems. <pre></pre> Write to Katherine Hamilton at katherine.hamilton@wsj.com <pre></pre> (END) Dow Jones Newswires June 03, 2026 09:49 ET (13:49 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

MMED

雅培

MiniMed 的股票在盘前交易中上涨了 7%，达到 13.14 美元，此前公司报告第四季度营收为 8.37 亿美元，超出预期。增长主要得益于国际销售增长 22%。此外，MiniMed 还扩大了与雅培的合作伙伴关系，以商业化其智能给药系统的葡萄糖 - 酮传感器

MiniMed 股价因第四季度销售增长及与雅培合作伙伴关系的扩展而上涨